FDA advisers vote for Covid-19 vaccine update to target single latest variant

Per AP News

With Covid-19 reportedly mutating with new variants coming out even after the vaccine's release, the FDA has called for an update to the current shots. FDA advisers voted that the new vaccine should target the single latest variant.

This comes as the current shots still include the original strain of the virus. During that time, FDA vaccine chief DR. Peter Marks gave a statement regarding the thought behind the decision.

Marks: “We’re concerned that we may have another wave of COVID-19 during a time when the virus has further evolved, immunity of the population has waned further, and we move indoors for wintertime,”

This comes as Americans were told by the FDA to expect an upcoming updated Covid-19 vaccine, just like the regular fall flu shots. However, it was reported that only 17% of Americans got a combo booster for the original strait plus the most common omicron variants of 2022.

In March, Biden reportedly signed a bill to declassify Covid-19 origins intelligence. Implementing the legislation would then declassify more information, which would then be accessible to the public.

In October, it was reported that scientists made a new Covid-19 variant that had an 80% kill rate in mice. This was according to a research paper that detailed how the study hopes to better understand the virus' protein spike effects.

See flow at unusualwhales.com/flow.

Other News:

Resources:

AP News

tastytrade logo+
Get the best broker for options trading and earn Unusual Whales discounted! in cash with an eligible account deposit at tastytrade. Get an Unusual Whales bonus when you deposit $2000. Offer expires 3/31/25. Certain restrictions, terms and conditions apply.
Unusual Whales does not confirm the information's truthfulness or accuracy of the associated references, data, and cannot verify any of the information. Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Options, investing, trading is risky, and losses are more expected than profits. Please do own research before investing. Please only subscribe after reading our full terms and understanding options and the market, and the inherent risks of trading. It is highly recommended not to trade on this, or any, information from Unusual Whales. Markets are risky, and you will likely lose some or all of your capital. Please check our terms for full details.
Any content on this site or related pages are not intended to provide legal, tax, investment or insurance advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. Nothing on Unusual Whales should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Unusual Whales or any third party. Certain investment planning tools available on Unusual Whales may provide general investment education based on your input. You are solely responsible for determining whether any investment, investment strategy, security or related transaction is appropriate for you based on your personal investment objectives, financial circumstances and risk tolerance. You should consult your legal or tax professional regarding your specific situation. See terms for more information.